Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but ...

Mersana Therapeutics, Inc.’s MRSN share price has dipped by 8.13%, which has investors questioning if this is right time to ...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

A nylon maker goes bankrupt, a carbon capture start-up raises money, Germany’s Merck acquires SpringWorks, and more ...

The global large granular lymphocytic leukemia therapeutics market is poised for significant expansion over the next decade, underpinned by improvements in diagnostic capabilities, the development of ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

Young minds will get a chance to dive into artificial intelligence and hands-on science as MilliporeSigma's mobile lab, the ...

Merck & Co. is caught in the middle of Wall Street's version of a group chat disagreement. Analysts gave it a “Moderate Buy” ...